Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
1. 系统已在2025-04-15 16:11:17对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/JCO.22.01010
文献链接: https://ascopubs.org/doi/10.1200/JCO.22.01010
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Jacobus Pfisterer; Florence Joly; Gunnar Kristensen; Joern Rau; Sven Mahner; Patricia Pautier; Ahmed El-Balat; Jean-Emmanuel Kurtz; Ulrich Canzler; Jalid Sehouli; Martin L. Heubner; Andreas D. Hartkopf; Klaus Baumann; Annette Hasenburg; Lars C. Hanker; Antje Belau; Barbara Schmalfeldt; Dominik Denschlag; Tjoung-Won Park-Simon; Frédéric Selle; Christian Jackisch; Alexander Burges; Hans-Joachim Lück; Günter Emons; Werner Meier; Martina Gropp-Meier; Willibald Schröder; Nikolaus de Gregorio; Felix Hilpert; Philipp Harter